Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights

This article was originally published in Scrip

Executive Summary

Exelixis Inc. will bring in $260m in up front and milestone payments in 2016 alone under its new partnership with Ipsen for ex-US development and commercialization of Cometriq (cabozantinib), while the company awaits both US and EU approvals of the drug for a form of kidney cancer.


Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts